Summary of different experimental approaches to model the MM BM microenvironment: Potential applications.
Multiple Myeloma (MM) develops almost exclusively within the Bone Marrow (BM), highlighting the critical role of the microenvironment in conditioning disease progression and resistance to drugs. Indeed, while the therapeutic armamentarium for MM has significantly improved over the past 20 years, the disease remains ultimately incurable. This failure may depend on the high phenotypic and genetic heterogeneity of MM, but also on the paucity and inadequacy of two-dimensional (2D) conventional preclinical models in reproducing MM within the BM. In the present paper, we provide a brief updated overview on MM BM microenvironment. We then discuss newly developed preclinical models mimicking MM/microenvironment interactions, including three-dimensional (3D), gel-based, in vitro models and a novel ex vivo system of isolated tumor and stromal cells cultured in bioreactor. Potential applications of each model, relative to investigation of MM pathogenic mechanisms and prediction of the best drug/combination for each individual patient will be also evaluated.
- multiple myeloma
- tumor microenvironment
- 2D/3D culture models
- 3D culture in bioreactor
- drug testing
- personalized therapy
Multiple Myeloma (MM) is a B-cell tumor characterized by clonal proliferation of malignant plasma cells (PC) inside the bone marrow (BM), production of a monoclonal paraprotein and associated clinical features, including hypercalcemia, renal failure, anemia and lytic bone lesions (CRAB features) [1, 2].
MM is the second most common hematological malignancy and is responsible for approximately 20% of deaths from hematological tumors. Despite significant advances in therapy over the past two decades, the disease remains incurable, and more than 90% of MM patients eventually become refractory to therapy and relapse [1, 2].
MM develops along an evolutionary process, leading a normal PC to the pre-malignant state of monoclonal gammopathy of uncertain significance (MGUS), an intermediate asymptomatic but more advanced pre-malignant state referred to as smoldering MM (SMM) and finally to symptomatic MM [3, 4, 5, 6]. This process is driven by the accumulation of cytogenetic modifications in PC. Indeed, while MM is still considered a single disease entity, it should be viewed as a collection of several different cytogenetically distinct PC tumors . Cytogenetic abnormalities encompass translocations involving the immunoglobulin heavy chain (IgH) gene locus on chromosome 14q32 and hyperdiploidy (particularly trisomies), as initiating events . IgH translocations include t(4;14), t(6;14), t(11;14), t(14;16) and t(14;20) translocations, which place the oncogenes Multiple Myeloma SET domain (MMSET)/ fibroblast growth factor receptor 3 (FGFR3), cyclin D3 (CCND3), CCND1, MAF, and MAFB, respectively, under the control of the strong enhancers of the Ig loci. This in turn leads to over-expression of cyclin D protein family members, ultimately driving G1/S checkpoint dysregulation [9, 10]. Hyperdiploidy, which is associated with the gain of the odd numbered chromosomes, including chromosome 3, 5, 7, 9, 11, 15, 19 and 21, also affects this checkpoint, implicating cyclin D dysregulation as an early and unifying oncogenic event in MM . Subsequent studies demonstrated that other cytogenetic changes termed secondary cytogenetic abnormalities, including gain(1q), del(1p), del(17p), del(13), RAS mutations and secondary translocations involving MYC, arise along the disease course of MM, exacerbating the cell cycle dysregulation and driving further proliferation and disease progression [10, 11]. Patients carrying del(17p), t(4;14), t(14;16), t(14;20), gain(1q), or p53 mutation, particularly when in combination (double-hit and triple-hit myeloma), are considered affected by high-risk MM , and represent an area of unmet clinical need .
In addition to genetic abnormalities, a characteristic feature of myeloma cells is the requirement for an intimate relationship with the BM microenvironment, where plasma cells are nurtured in specialized niches that maintain their long-term survival. Indeed, BM components deeply influence many steps of tumor progression, such as MM proliferation and invasion, angiogenesis and drug resistance [12, 13].
The BM, where MM cells specifically home mainly through the CXCR4/CXCL12-SDF1α axis , provides a highly specialized microenvironment, which optimally “soils” neoplastic PC, and, in turn, is shaped by the interactions with the tumor [15, 16]. The BM microenvironment comprises two major compartments,
Another key feature of the BM microenvironment is hypoxia. In the BM, oxygen (O2) tensions fluctuate throughout two specialized niches, the hypoxic endosteal niche and the oxygenated vascular niche, mapping areas with controlled, physiological O2 gradients, instrumental to hematopoietic stem cells homeostasis . BM homing is a common feature of hematological malignancies, that in proximity of hypoxic niches escape drug-inflicted apoptosis and acquire a drug-resistant phenotype. This is particularly true for MM that develops almost exclusively in the BM, where myeloma cells accumulation and the abnormal vasculature contribute to aggravate hypoxia. BM samples from MM patients as well as circulating MM cells are reported to have a hypoxic phenotype  and a strong stabilized expression of the hypoxia master regulator hypoxia-inducible factor (HIF)-1α protein . Notably, HIF-1α suppression in myeloma cells blocks tumor growth
Overall, the cross-talk between MM cells and their BM microenvironment results in autocrine/paracrine loops of MM survival/proliferation and also promotes the “angiogenic switch”, osteoclastogenesis, and defective immune functions [12, 13]. In particular, adhesion of MM cells to ECM components and to BMSC triggers classical survival signaling pathways including, but not limited to, the PI3K/AKT signaling pathway, anti-apoptotic signals and also the release of the pro-survival factor Interleukin (IL)-6 . MM cells-BM interactions also play a key role in disease pathogenesis. In particular, new blood vessel formation is considered a hallmark of MM development and is supported by the histopathological evidence of increased microvessel density (MVD), surrogate parameter endowed with prognostic significance, in the BM of MM patients . Angiogenesis, the sprouting of capillaries from existing blood vessels, is also suggested by the plethora of soluble angiogenic factors in the BM and in the peripheral blood (PB) samples from myeloma patients (vascular endothelial growth factor, VEGF; basic fibroblast growth factor, bFGF; angiopoietins, Angs) [29, 30], whose contribution to the process has been extensively reviewed . Moreover, the finding of an elevated number of circulating endothelial precursor cells (EPC) in MM patients indicates that complementary modalities to build vessels, e.g., vasculogenesis, are engaged . Finally, EC are by nature fine sensors of O2 variations, and the hypoxic microenvironment inside the BM significantly contributes to the induction of the “angiogenic switch” and the maintenance of the pro-angiogenic profile through the transcription of HIF-1α .
MM plasma cells and BM stroma also contribute to the pathophysiology of MM-associated bone disease through the activation of signaling pathways regulating osteoclastogenesis, particularly the RANK/RANK-Ligand (RANK-L) and the Wnt pathway, and the release of osteoclast-activating factors, such as IL-1, IL-6, tumor necrosis factor (TNF)-α, IL-8 and Macrophage Inflammatory Protein (MIP)-1α. These factors, together with recently identified dysregulated miRNAs, determine osteoblast suppression with excessive osteoclastic resorption . Finally, MM cells display a unique ability to evade immune surveillance through several mechanisms, including impairment of cytotoxic activity, induction of dendritic cell dysfunction and recruitment of regulatory cells .
2. 3D models of MM microenvironment for precision medicine
2.1 Therapeutic targeting of MM cells and their BM microenvironment: toward personalized therapy
Over the past 20 years, progressive understanding of the pathophysiology of MM has informed treatment paradigm and patients’ outcome . In particular, the introduction into the clinical practice of novel agents, such as proteasome inhibitors (PI) and immunomodulatory drugs (IMiDs), has prolonged median survival of MM patients from 3 to about 6 years, reaching approximatively 8 years in the subset of patients eligible to autologous stem cell transplantation (ASCT) .
The proteasome inhibitor bortezomib targets MM cells harnessing their dependency on the protein quality control pathway as a therapeutic target . The ubiquitin-proteasome system represents a major mechanism for maintaining protein homeostasis, which is strictly required by normal antibody secreting PC, and particularly by MM PC . Bortezomib causes an imbalance between proteasome degradative capacity and proteasome load, leading to the activation of the unfolded protein response, and ultimately to cell death
Given the key role of BM components in supporting MM cell proliferation, migration, survival and drug resistance, while also conferring immunosuppression, disrupting MM cells-BM interactions represents an alternative therapeutic strategy in MM. IMiDs, including thalidomide and its more potent derivatives lenalidomide and pomalidomide, have received Food and Drug Administration (FDA) approval for treatment of both newly diagnosed and relapsed/refractory MM . IMiDs bind to cereblon (CRBN) and activate CRBN E3-ligase activity, causing the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros (IKZF1) and Aiolos (IKZF3) [40, 41]. IMIDs thus exert direct cytotoxic effects on MM cells, including growth arrest, free radical-mediated DNA damage and caspase-8-mediated apoptosis; moreover, they modulate cytokine and growth factor secretion, inhibit angiogenesis, and, most importantly, upregulate T, NK, and NKT cytotoxicity, while downregulating regulatory T cells .
Over the disease course, however, MM cells acquire resistance to bortezomib and IMiDs through genetic and non-genetic mechanisms [36, 43]. To overcome resistance, second-generation PI (carfilzomib, ixazomib) and higher affinity CRBN E3-ligase modulators, such as iberdomide, have been developed [35, 36]. Alternative therapeutic approaches include: targeting epigenetic modifications
To date, therapy for an individual MM patient is selected based on clinical factors, such as age, performance status, comorbidities and eligibility for ASCT . Given the high heterogeneity of the disease in terms of underlying molecular aberrations and clinical course, and also the growing armamentarium of currently available effective agents, this approach can be updated by the use of evidence-based algorithms , but it also needs to be implemented by incorporating prognostic and predictive biomarkers for survival and response to treatment . Indeed, thanks to the progressive evolution and clinical utilization of molecular technologies, such as fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS), we can foresee that in the near future the choice of therapy may include selection of targeted treatments based on the presence of specific molecular lesions, thus achieving personalized cancer care for MM patients . Such treatments can be validated through randomized controlled clinical trials ; however, the development of reliable patient-specific pre-clinical models would also be valuable in the perspective of defining personalized, biologically based treatments for MM patients, while preventing ineffective therapy of resistant MM cells and unwanted toxicities .
models of cancer: moving from 2D to 3D In vitro
It is increasingly recognized that microenvironment plays a fundamental role in supporting tumor cell growth, survival and drug resistance; thus, experimental models of cancer should incorporate elements of the surrounding milieu to recreate and unveil the mechanisms that, at the molecular level, regulate the complex interplay between tumor cells and their embedding niche(s).
Traditional two-dimensional (2D)
Tissue engineering and regenerative medicine, originally aimed at developing biological substitutes of tissues or whole organs, have been subsequently extended to the generation of 3D platforms attempting to overcome the limitations of conventional culture models . These platforms are based on different approaches, also depending on the aims to be addressed . In particular, several experimental approaches rely on the use of polymeric substrates with tunable composition and stiffness, as scaffolds or hydrogel-based models. Scaffolds are key elements for the generation of 3D platforms, since they provide the mechanical support and physical composition for seeded cells to attach, grow and maintain their specialized functions. A suitable scaffold, such as a bone scaffold, must have favorable biocompatibility or cyto-compatibility and also adequate pore size and interconnectivity, in order to guarantee the growth, differentiation and proper penetration and distribution of different cell types . Hydrogels are meant to mimic the ECM, and can be either natural or synthetic, the former commonly made with natural polymers (fibrinogen, hyaluronic acid, collagen, Matrigel and gelatin). Synthetic hydrogels are instead typically made with synthetic polymers (polyethylene glycol, polylactic acid, or poly-vinyl acetate) .
Scaffold-free models include spheroids and organoids. Spheroids are clusters of cells forced to assemble through hanging drop techniques or culture in bioreactor, taking advantage of the ability of cultured tumor cells to self-aggregate . Spheroids derived from tumor cells, commonly referred to as tumorspheres, are typically monocultures, and therefore lack the multicellular identity that exists in a tumor
2.3 3D models of multiple myeloma
Since hematological malignancies with BM homing are supported by specialized niches, the complex BM architecture, together with cellular and molecular composition and interactions, needs to be replicated in engineered platforms to reproduce blood cancer behavior . Indeed, while 2D cultures of established MM cell lines have been extensively used in high-throughput drug screening, they fail to reproduce BM microenvironment as well as the heterogeneity of MM patients’ cells. The use of primary patient-derived MM cells in 2D monocultures or in co-cultures with stromal cells maintains the heterogeneity of the sample, but MM cell viability and functional interactions are often limited . Finally, several animal models, which have been reviewed elsewhere [62, 63, 64, 65], have been developed in order to support the growth of primary myeloma cells within a 3D microenvironment. While these models are more complex and therefore considered as more relevant, they are not representative of the human microenvironment. Within this context, 3D
Herein we describe relevant 3D models of MM BM microenvironments that were generated exploiting different technical approaches,
2.3.1 3D platforms using gel scaffolds
In 2008, Kirshner and co-workers reported the first
More recently, de la Puente et al.  developed a novel patient-derived 3D tissue-engineered BM culture model complexing BM supernatant of MM patients and autologous cells in a gel scaffold prepared from patient-derived plasma fibrinogen. The resulting construct contained all the growth factors, enzymes and cytokines naturally found in the MM microenvironment of an individual patient, better recapitulating the BM niche. The model reproduced the MM BM hypoxic gradients; moreover, it allowed
An additional attempt to mimic the MM niche was performed by Jakubikova and colleagues , who developed a new 3D co-culture
Finally, a further advancement was reported by Braham
2.3.2 3D platforms using silk scaffolds
Adopting a different strategy, based on the use of a strong, porous silk scaffold, MSC were induced to undergo osteogenic differentiation, recreating a mineralized 3D bone matrix . The model allowed to reproduce proper MM-bone interactions in a standardized context and to study the MM-associated osteogenic process, demonstrating the negative impact of myeloma cells on normal bone homeostasis . 3D silk scaffolds have also been employed by the same group to develop the first 3D, tissue-engineered BM adipose tissue (MAT) model, useful for elucidating the reciprocal interactions between MAT and tumor cells .
2.3.3 3D models using microfluidics
Recent technical advances include the tumor lab-on-a-chip,
2.3.4 3D culture of human MM tissue explants and of isolated MM cells in scaffolds in the microgravity-based RCCS™ bioreactor
The metabolic requirements of complex 3D cell constructs are substantially higher than those needed for the maintenance of traditional 2D cultures under static conditions. To meet this demand, dynamic bioreactors were primarily developed to optimize mass transfer, that is, gas/nutrient supply and waste elimination, all essential factors for preserving cell viability within large 3D cell/tissue masses. Among a wide array of fluid-dynamic bioreactors, the best conditions for long-term culture of functional 3D tissue-like bio-constructs and explants of various origin, including bone, were obtained with the introduction of the microgravity-based Rotary Cell Culture System (RCCS™, Synthecon Inc., USA) bioreactor [77, 78, 79] (a vast literature is available at http://www.synthecon.com). On this basis, we successfully employed the microgravity-based RCCS™ technology for the generation and long-term maintenance of viable human-derived MM tissue explants and 3D cell constructs. Our experimental procedure for culturing human tissue samples was firstly validated by using normal (skin and BM) and tumor biopsies . Then, 3D culture of human MM tissue explants was found to maintain overall histo-architecture integrity and viability for up to two weeks. Moreover, the system was suitable for assessing the impact of drugs not only on MM cells, but also on angiogenic vessels, as evaluated through the assessment of MVD . Finally, specialized functions of both MM cells and their microenvironment, including beta-2 microglobulin and cytokine release and metalloproteases activities, could be also assessed . Overall, these observations suggest that 3D culture of MM tissues in bioreactor is feasible and can be potentially exploited as a novel translational tool for patient-specific drug testing.
A major limitation to a systematic pre-clinical use of this approach, however, is represented by the restricted availability of human MM biopsies for tissue culture, besides those obtained for diagnostic purposes. To overcome this limitation, we have recently established a novel procedure based on the reconstruction of a 3D surrogate MM BM microenvironment . This model relies on the co-seeding of MM cells and stroma inside a gelatin sponge, which is subsequently cultured in bioreactor. Figure 1 schematically represents the procedure developed to generate MM BM surrogate microenvironments, as well as the information that can be obtained through the analysis of both repopulated scaffolds and culture supernatants. Myeloma cell lines engaged contacts with stromal cells, EC and osteoblasts, as assessed by histochemical and electron-microscopic analyses. Consistently, pro-survival signaling and also CAM-DR, particularly through the engagement of the integrin VLA-4 by its counter-receptor VCAM1 , were significantly higher in 3D than in 2D parallel co-cultures. Soluble factor-mediated drug resistance could be also appreciated in 3D co-cultures. The system was then successfully applied to co-cultures of primary myeloma cells-primary myeloma BMSC and EC, allowing the functionalization of myeloma-stroma interactions and MM cell long-term survival. Finally, the impact of bortezomib on myeloma cells and on specialized functions of the microenvironment could be evaluated. Significantly, the model also showed the potential for assessing clonal evolution
Further studies validated the use of the model for additional purposes, including investigation on novel pathogenic interactions and preclinical drug testing. In particular, modeling the interaction between the receptor tyrosine kinase ROR2 and its ligand WNT5A in bioreactor allowed identifying this pathway as crucial in the adhesion of MM cells to the BM microenvironment, and as a potential therapeutic target for the large subgroup of MM patients whose cancer cells show ROR2 overexpression . Moreover, the use of surrogate MM microenvironments in bioreactor complemented studies performed both
Our surrogate BM microenvironment could also be exploited for other hematological malignancies infiltrating the BM niches. In particular, Chronic Lymphocytic Leukemia (CLL) is characterized by a progressive expansion of clonal CD5+ B lymphocytes that dynamically traffic from PB to the more protective BM and secondary lymphoid organs, where they acquire an aggressive phenotype and drug resistance . In this context, new targeted therapies, namely kinase inhibitors (KI), have been developed to promote mobilization of leukemic cells from the hosting tissues into the PB, where they may re-acquire sensitivity to drug-induced apoptosis . Our 3D surrogate BM microenvironment was exploited to recreate the niche-specific interplay involved in CLL cells homing/mobilization, showing that distinct molecular interactions, in particular through the HS1 cytoskeletal protein, were reproduced . We could demonstrate that HS1 conversion from the active to the inactive form, promoted by the KI ibrutinib, was able to regulate CLL cells retention inside- and mobilization from- scaffolds. This indicates that the model may serve as a good platform to unveil the mechanisms underlying tumor cells dissemination and to predict the impact of mobilizing agents , conceivably also in MM.
3. Conclusions and perspectives
The BM, where MM cells home, survive and accumulate, represents a complex and highly specialized tumor microenvironment, making the development of engineered 3D platforms of MM a challenging task. Indeed, in addition to a series of distinct ECM and cellular components, the BM microenvironment comprises several factors, including specialized niches, hypoxic gradients, vascularization and a mineralized matrix, all to be taken into account to faithfully recapitulate the native tumor. Nevertheless, already available pre-clinical models of MM represent a remarkable example of translational cancer research , potentially covering issues ranging from high- throughput drug assessment/screening to investigation on MM pathophysiology and patient-tailored drug testing aimed at precision oncology. Table 1 summarizes the main features of the previously described 3D models of MM BM microenvironments, together with their suitability, in our view, to different purposes. In particular, microfluidic systems could be exploited for drug screening/development with high-throughput potential, in that they can be miniaturized to cope with the limited biological starting material than can be obtained from MM patients’ samples. Most of the 3D platforms can be used in principle to test a selected range of drugs in a more precise microenvironmental context, in the perspective of personalized therapy and prediction of resistance. Finally, complex 3D technologies, such as bioreactor-based dynamic culture systems, while less easy to handle, can be tuned to recreate proper MM milieu and interactions, thus being suitable to investigation on MM pathophysiology and the mechanisms of drugs. Future efforts combining interdisciplinary basic and technical proficiencies, in particular related to tissue engineering, new biomaterials and advanced imaging techniques [48, 89], are expected to generate fully-humanized, simple, cost-effective, reliable and standardized models that can be more widely employed in the pre-clinical setting, particularly in high-risk and in relapsed/resistant MM patients.
|3D model||Reference||Composition||Drug tested||Drug screening||Precision Oncology||MM biology|
|Gel scaffold||Kirshner et al., 2008 ||ECM components + MM BM aspirates||Melphalan,|
|Gel scaffold||de la Puente et al., 2015 ||Fibrin gel + MM cells + BMSC/EC||Btz, Cfz||—||+||+|
|Gel scaffold||Jakubikova et al., 2016 ||PuraMatrix hydrogel +primary MM cells + BMSC||iMiDs, Btz, Cfz DOXO, DEX, Melphalan||—||+||+|
|Gel scaffold||Braham et al., 2018 ||Matrigel+ BMSC +EC + MM cells||TEGs ( T cells expressing V9 V2 TCRs)||—||+||+|
|Solid scaffold||Reagan et al., 2014|
|Silk scaffold+ MM cells +BMSC/EC||Btz||—||+||+|
|Solid scaffold||Fairfield et al., 2019 ||Silk scaffold+ MM cell lines+ BMSC||none||—||—||+|
|Microfluidics||Young et al., 2012 ||Microchambers +MM cell lines +BMSC||Btz||+||+||—|
|Bioreactor-based||Belloni et al., 2018 ||Gelatin scaffolds populated by MM cell lines/primary MM cells + BMSC/EC/OB cultured in bioreactor||Btz, Melphalan,|
|Bioreactor-based||Bonomi et al., 2017 ||Spheroids of MM cell lines + BMSC cultured in bioreactor||Paclitaxel||—||+||—|
In addition to the purpose of precision oncology, 3D platforms can be applied to explore novel pathogenic cues. In particular, several matters that are object of intense investigation, including hypoxia and tumor metabolism, as well as the contribution of exosomes and miRNAs in the interactions between tumor and its co-evolving microenvironment, could be fruitfully and more precisely investigated applying advanced technological approaches, as already done in different settings (Figure 1 and [90, 91]). Further exploitation of the SCID/scaffold model, based on the transplantation of 3D bone-like polymeric scaffolds into immunocompromised mice, can also be envisaged to dissect biological events in primary MM cells engrafted inside a human BM microenvironment, as well as their response to drug in a
We wish to thank Dr. Antonello Villa (Università Milano Bicocca, Milan, Italy) for his outstanding contribution in generating confocal, immunohistochemistry and electron-microscopy images; Dr. Daniela Belloni (Division of Experimental Oncology, San Raffaele Scientific Institute, Milan, Italy) for developing the 3D model in bioreactor and performing experiments; Prof Federico Caligaris-Cappio (Italian Association for Cancer Research-AIRC) and Dr. Giovanni Tonon (Division of Experimental Oncology, San Raffaele Scientific Institute, Milan, Italy) for helpful discussion and unceasing support; Prof. Paolo Ghia (Division of Experimental Oncology, San Raffaele Scientific Institute, Milan, Italy) for precious insights.
Conflict of interest
The authors declare no Conflict of Interest.
Papers from our group cited in this chapter were partially supported by the AIRC 5x1000 Project n 9965 (to Prof Federico Caligaris Cappio) and its extension (to Prof Paolo Ghia).
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48. DOI: 10.1016/S1470-2045(14)70442-5
Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F, Anderson KC. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046. DOI: 10.1038/nrdp.2017.46
Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood. 1996;88(2):674-81
Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, Blood E, Oken MM, Santana-Dávila R, González-Paz N, Kyle RA, Gertz MA, Dispenzieri A, Lacy MQ , Greipp PR. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102(7):2562-7. DOI: 10.1182/blood-2003-02-0493
González D, van der Burg M, García-Sanz R, Fenton JA, Langerak AW, González M, van Dongen JJ, San Miguel JF, Morgan GJ. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood. 2007;110(9):3112-21. DOI: 10.1182/blood-2007-02-069625
Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017;17(9):543-556. DOI: 10.1038/nrc.2017.63
Kumar SK, Rajkumar SV. The multiple myelomas - current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018;15(7):409-421. DOI: 10.1038/s41571-018-0018-y
Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2019;133(7):660-675. DOI: 10.1182/blood-2018-09-825331
Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106(1):296-303. DOI: 10.1182/blood-2005-01-0034
Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335-48. DOI: 10.1038/nrc3257
Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020 May;95(5):548-567. DOI: 10.1002/ajh.25791
Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007:585-98. DOI: 10.1038/nrc2189
Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114(16):3367-75. DOI: 10.1182/blood-2009-06-225326
Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, Spencer JA, Kimlinger T, Ghobrial JM, Jia X, Lu G, Timm M, Kumar A, Côté D, Veilleux I, Hedin KE, Roodman GD, Witzig TE, Kung AL, Hideshima T, Anderson KC, Lin CP, Ghobrial IM. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007;109(7):2708-17. DOI: 10.1182/blood-2006-07-035857
Tripodo C, Sangaletti S, Piccaluga PP, Prakash S, Franco G, Borrello I, Orazi A, Colombo MP, Pileri SA. The bone marrow stroma in hematological neoplasms--a guilty bystander. Nat Rev Clin Oncol. 2011;8(8):456-66. DOI: 10.1038/nrclinonc.2011.31
Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia. 2006;20(2):193-9. DOU: 10.1038/sj.leu.2404067
Boyiadzis M, Whiteside TL. The emerging roles of tumor-derived exosomes in hematological malignancies. Leukemia. 2017;31(6):1259-1268. DOI: 10.1038/leu.2017.91
Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, Anderson KC, Scadden DT, Ghobrial IM. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013;123(4):1542-55. DOI: 10.1172/JCI66517
Colombo M, Giannandrea D, Lesma E, Basile A, Chiaramonte R. Extracellular Vesicles Enhance Multiple Myeloma Metastatic Dissemination. Int J Mol Sci. 2019;20(13):3236. DOI: 10.3390/ijms20133236
Raimondo S, Urzì O, Conigliaro A, Raimondi L, Amodio N, Alessandro R. Emerging Insights on the Biological Impact of Extracellular Vesicle-Associated ncRNAs in Multiple Myeloma. Noncoding RNA. 2020;6(3):30. DOI: 10.3390/ncrna6030030
Muz B, de la Puente P, Azab F, Luderer M, Azab AK. The role of hypoxia and exploitation of the hypoxic environment in hematologic malignancies. Mol Cancer Res. 2014;12(10):1347-54. DOI: 10.1158/1541-7786.MCR-14-0028
Colla S, Storti P, Donofrio G, Todoerti K, Bolzoni M, Lazzaretti M, Abeltino M, Ippolito L, Neri A, Ribatti D, Rizzoli V, Martella E, Giuliani N. Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia. 2010;24(11):1967-70. DOI: 10.1038/leu.2010.193
Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399-408. DOI: 10.1016/j.cell.2012.01.021
Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D, Martella E, Lazzaretti M, Mancini C, Agnelli L, Patrene K, Maiga S, Franceschi V, Colla S, Anderson J, Neri A, Amiot M, Aversa F, Roodman GD, Giuliani N. Hypoxia-inducible factor (HIF)-1alpha suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia. 2013 27(8):1697-1706. DOI: 10.1038/leu.2012.190
Ohyashiki JH, Umezu T, Ohyashiki K. Exosomes promote bone marrow angiogenesis in hematologic neoplasia: the role of hypoxia. Curr Opin Hematol. 2016;23(3):268-73. DOI: 10.1097/MOH.0000000000000235
Maiso P, Huynh D, Moschetta M, Sacco A, Aljawai Y, Mishima Y, Asara JM, Roccaro AM, Kimmelman AC, Ghobrial IM. Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res. 2015 May 15;75(10):2071-82. DOI: 10.1158/0008-5472.CAN-14-3400
Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells. 2006;24(4):986-91. DOI: 10.1634/stemcells.2005-0220
Sezer O, Niemöller K, Eucker J, Jakob C, Kaufmann O, Zavrski I, Dietel M, Possinger K. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol. 2000;79(10):574-7. DOI: 10.1007/s002770000236
Ribatti D, Nico B, Vacca A. Multiple myeloma as a model for the role of bone marrow niches in the control of angiogenesis. Int Rev Cell Mol Biol. 2015;314:259-82. DOI: 10.1016/bs.ircmb.2014.10.004
Belloni D, Marcatti M, Ponzoni M, Ciceri F, Veschini L, Corti A, Caligaris Cappio F, Ferrarini M, Ferrero E. Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis. Exp Cell Res. 2015;330(1):1-12. DOI: 10.1016/j.yexcr.2014.10.017
Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia. 2006;20(2):193-9. DOI: 10.1038/sj.leu.2404067
Ferrarini M, Ferrero E. Proteasome inhibitors and modulators of angiogenesis in multiple myeloma. Curr Med Chem. 2011;18(34):5185-95. DOI: 10.2174/092986711798184316
Raimondi L, De Luca A, Giavaresi G, Raimondo S, Gallo A, Taiana E, Alessandro R, Rossi M, Neri A, Viglietto G, Amodio N. Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology. Noncoding RNA. 2020;6(3):E37. DOI: 10.3390/ncrna6030037
Kawano Y, Moschetta M, Manier S, Glavey S, Görgün GT, Roccaro AM, Anderson KC, Ghobrial IM. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015;263(1):160-72. DOI: 10.1111/imr.12233
Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica. 2020 Jul 23:haematol.2020.247015. DOI: 10.3324/haematol.2020.247015
Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017;36(4):561-584. DOI: 10.1007/s10555-017-9707-8
Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F, Orsi A, Pasqualetto E, Mezghrani A, Calbi V, Palladini G, Giuliani N, Anderson KC, Sitia R, Cenci S. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009;113(13):3040-9. DOI: 10.1182/blood-2008-08-172734
Belloni D, Veschini L, Foglieni C, Dell'Antonio G, Caligaris-Cappio F, Ferrarini M, Ferrero E. Bortezomib induces autophagic death in proliferating human endothelial cells. Exp Cell Res. 2010;316(6):1010-8. DOI: 10.1016/j.yexcr.2009
Hideshima T, Anderson KC. Biologic impact of proteasome inhibition in multiple myeloma cells-from the aspects of preclinical studies. Semin Hematol. 2012;49(3):223-7. DOI: 10.1053/j.seminhematol.2012.04.006
Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, Ciarlo C, Hartman E, Munshi N, Schenone M, Schreiber SL, Carr SA, Ebert BL. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301-5. DOI: 10.1126/science.1244851
Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG Jr. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343(6168):305-9. DOI: 10.1126/science.1244917
Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010;24 Suppl 1:S13-9. DOI: 10.1016/S0268-960X(10)70004-7
Martinez-Høyer S, Karsan A. Mechanisms of lenalidomide sensitivity and resistance. Exp Hematol. 2020:S0301-472X(20)30561-0. DOI: 10.1016/j.exphem.2020.09.196. Epub ahead of print
Boussi L, Niesvizky R. Advances in immunotherapy in multiple myeloma. Curr Opin Oncol. 2017;29(6):460-466. DOI: 10.1097/CCO.0000000000000407
Norelli M, Casucci M, Bonini C, Bondanza A. Clinical pharmacology of CAR-T cells: Linking cellular pharmacodynamics to pharmacokinetics and antitumor effects. Biochim Biophys Acta. 2016;1865(1):90-100. DOI: 10.1016/j.bbcan.2015.12.001
Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9):94. DOI: 10.1038/s41408-020-00359-2
Papadimitriou K, Kostopoulos IV, Tsopanidou A, Orologas-Stavrou N, Kastritis E, Tsitsilonis O, Dimopoulos MA, Terpos E. Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma. Cancers (Basel). 2020;12(8):2006. DOI: 10.3390/cancers12082006
Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol. 2007;8(10):839-45. DOI: 10.1038/nrm2236
Jensen C, Teng Y. Is It Time to Start Transitioning From 2D to 3D Cell Culture? Front Mol Biosci. 2020;7:33. DOI: 10.3389/fmolb.2020.00033
Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods. 2007;4(4):359-65. DOI: 10.1038/nmeth1015
Chang TT, Hughes-Fulford M. Monolayer and spheroid culture of human liver hepatocellular carcinoma cell line cells demonstrate distinct global gene expression patterns and functional phenotypes. Tissue Eng Part A. 2009;15(3):559-67. DOI: 10.1089/ten.tea.2007.0434
Pickl M, Ries CH. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene. 2009;28(3):461-8. DOI: 10.1038/onc.2008.394
Riedl A, Schlederer M, Pudelko K, Stadler M, Walter S, Unterleuthner D, Unger C, Kramer N, Hengstschläger M, Kenner L, Pfeiffer D, Krupitza G, Dolznig H. Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses. J Cell Sci. 2017;130(1):203-218. DOI: 10.1242/jcs.188102
Clara-Trujillo S, Gallego Ferrer G, Gómez Ribelles JL. In Vitro Modeling of Non-Solid Tumors: How Far Can Tissue Engineering Go? Int J Mol Sci. 2020;21(16):5747. DOI: 10.3390/ijms21165747
Carletti E, Motta A, Migliaresi C. Scaffolds for tissue engineering and 3D cell culture. Methods Mol Biol. 2011;695:17-39. doi: 10.1007/978-1-60761-984-0_2
Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol. 2010;148(1):3-15. DOI: 10.1016/j.jbiotec.2010.01.012
Yin X, Mead BE, Safaee H, Langer R, Karp JM, Levy O. Engineering Stem Cell Organoids. Cell Stem Cell. 2016;18(1):25-38. DOI: 10.1016/j.stem.2015.12.005
Smith AR, Kuo CJ. Organoids lead the cancer attack. Nat Med. 2017;23(12):1399-1400. DOI: 10.1038/nm.4454
Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18(7):407-418. DOI: 10.1038/s41568-018-0007-6
Datta P, Dey M, Ataie Z, Unutmaz D, Ozbolat IT. 3D bioprinting for reconstituting the cancer microenvironment. NPJ Precis Oncol. 2020;4:18. DOI: 10.1038/s41698-020-0121-2
Meng F, Meyer CM, Joung D, Vallera DA, McAlpine MC, Panoskaltsis-Mortari A. 3D Bioprinted In Vitro Metastatic Models via Reconstruction of Tumor Microenvironments. Adv Mater. 2019;31(10):e1806899. DOI: 10.1002/adma.201806899
Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev. 2003;194:196-206. DOI: 10.1034/j.1600-065x.2003.00035.x
Ferrarini M, Mazzoleni G, Steimberg N, Belloni D, Ferrero E. Innovative models to assess Multiple Myeloma biology and the impact of drugs. In Hajek R, editor. Multiple Myeloma – A quick reflection on the fast progress. InTechOpen; 2013, p 39-60. DOI:10.5772/54312
Rossi M, Botta C, Arbitrio M, Grembiale RD, Tagliaferri P, Tassone P. Mouse models of multiple myeloma: technologic platforms and perspectives. Oncotarget. 2018;9(28):20119-20133. DOI: 10.18632/oncotarget.24614
Cooke RE, Koldej R, Ritchie D. Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help? J Oncol. 2019;2019:2186494. DOI:10.1155/2019/2186494
Kirshner J, Thulien KJ, Martin LD, Debes Marun C, Reiman T, Belch AR, Pilarski LM. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood. 2008;112(7):2935-45. DOI: 10.1182/blood-2008-02-142430
de la Puente P, Muz B, Gilson RC, Azab F, Luderer M, King J, Achilefu S, Vij R, Azab AK. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. Biomaterials. 2015;73:70-84. DOI: 10.1016/j.biomaterials.2015.09.017
Jakubikova J, Cholujova D, Hideshima T, Gronesova P, Soltysova A, Harada T, Joo J, Kong SY, Szalat RE, Richardson PG, Munshi NC, Dorfman DM, Anderson KC. A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget. 2016;7(47):77326-77341. DOI: 10.18632/oncotarget.12643
Braham MVJ, Minnema MC, Aarts T, Sebestyen Z, Straetemans T, Vyborova A, Kuball J, Öner FC, Robin C, Alblas J. Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model. Oncoimmunology. 2018;7(6):e1434465. DOI: 10.1080/2162402X.2018.1434465
Marcu-Malina V, Heijhuurs S, van Buuren M, Hartkamp L, Strand S, Sebestyen Z, Scholten K, Martens A, Kuball J. Redirecting αβ T cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor. Blood. 2011;118(1):50-9. DOI: 10.1182/blood-2010-12-325993
Reagan MR, Mishima Y, Glavey SV, Zhang Y, Manier S, Lu ZN, Memarzadeh M, Zhang Y, Sacco A, Aljawai Y, Shi J, Tai YT, Ready JE, Kaplan DL, Roccaro AM, Ghobrial IM. Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood. 2014;124(22):3250-9. DOI: 10.1182/blood-2014-02-558007
Fairfield H, Falank C, Farrell M, Vary C, Boucher JM, Driscoll H, Liaw L, Rosen CJ, Reagan MR. Development of a 3D bone marrow adipose tissue model. Bone. 2019;118:77-88. DOI: 10.1016/j.bone.2018.01.023
Nguyen NT, Shaegh SA, Kashaninejad N, Phan DT. Design, fabrication and characterization of drug delivery systems based on lab-on-a-chip technology. Adv Drug Deliv Rev. 2013;65(11-12):1403-19. DOI: 10.1016/j.addr.2013.05.008
Torisawa YS, Spina CS, Mammoto T, Mammoto A, Weaver JC, Tat T, Collins JJ, Ingber DE. Bone marrow-on-a-chip replicates hematopoietic niche physiology in vitro. Nat Methods. 2014;11(6):663-9. DOI: 10.1038/nmeth.2938
Young EW, Pak C, Kahl BS, Yang DT, Callander NS, Miyamoto S, Beebe DJ. Microscale functional cytomics for studying hematologic cancers. Blood. 2012;119(10):e76-85. DOI: 10.1182/blood-2011-10-384347
Pak C, Callander NS, Young EW, Titz B, Kim K, Saha S, Chng K, Asimakopoulos F, Beebe DJ, Miyamoto S. MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells. Integr Biol (Camb). 2015;7(6):643-54. DOI: 10.1039/c5ib00071h
Navran S. The application of low shear modeled microgravity to 3-D cell biology and tissue engineering. Biotechnol Annu Rev. 2008;14:275-96. DOI: 10.1016/S1387-2656(08)00011-2
Grimm D, Wehland M, Pietsch J, Aleshcheva G, Wise P, van Loon J, Ulbrich C, Magnusson NE, Infanger M, Bauer J. Growing tissues in real and simulated microgravity: new methods for tissue engineering. Tissue Eng Part B Rev. 2014;20(6):555-66. DOI: 10.1089/ten.TEB.2013.0704
Cosmi F, Steimberg N, Dreossi D, Mazzoleni G. Structural analysis of rat bone explants kept in vitro in simulated microgravity conditions. J Mech Behav Biomed Mater. 2009;2(2):164-72. DOI: 10.1016/j.jmbbm.2008.06.004
Ferrarini M, Steimberg N, Ponzoni M, Belloni D, Berenzi A, Girlanda S, Caligaris-Cappio F, Mazzoleni G, Ferrero E. Ex-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of Multiple Myeloma biology and response to therapy. PLoS One. 2013;8(8):e71613. DOI: 10.1371/journal.pone.0071613
Belloni D, Heltai S, Ponzoni M, Villa A, Vergani B, Pecciarini L, Marcatti M, Girlanda S, Tonon G, Ciceri F, Caligaris-Cappio F, Ferrarini M, Ferrero E. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment. Haematologica. 2018;103(4):707-716. DOI: 10.3324/haematol.2017.167486
Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, Nobuyoshi M, Oh I, Sato K, Suzuki T, Ozaki K, Mori M, Nagai T, Muroi K, Kano Y, Furukawa Y, Ozawa K. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene. 2009;28(2):231-42. DOI: 10.1038/onc.2008.385
Frenquelli M, Caridi N, Antonini E, Storti F, Viganò V, Gaviraghi M, Occhionorelli M, Bianchessi S, Bongiovanni L, Spinelli A, Marcatti M, Belloni D, Ferrero E, Karki S, Brambilla P, Martinelli-Boneschi F, Colla S, Ponzoni M, DePinho RA, Tonon G. The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation. Leukemia. 2020;34(1):257-270. DOI: 10.1038/s41375-019-0486-9
Botrugno OA, Bianchessi S, Zambroni D, Frenquelli M, Belloni D, Bongiovanni L, Girlanda S, Di Terlizzi S, Ferrarini M, Ferrero E, Ponzoni M, Marcatti M, Tonon G. ATR addiction in multiple myeloma: synthetic lethal approaches exploiting established therapies, Haematologica (e-pub ahead of print)
Thompson PA, Burger JA. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Expert Opin Investig Drugs. 2018;27(1):31-42. DOI: 10.1080/13543784.2018.1404027
Barbaglio F, Belloni D, Scarfò L, Sbrana FV, Ponzoni M, Bongiovanni L, Pavesi L, Zambroni D, Stamatopoulos K, Caiolfa VR, Ferrero E, Ghia P, Scielzo C. 3D co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents. Haematologica. 2020 Jul 30:haematol.2020.248112. DOI: 10.3324/haematol.2020.248112. Epub ahead of print
Bonomi A, Steimberg N, Benetti A, Berenzi A, Alessandri G, Pascucci L, Boniotti J, Coccè V, Sordi V, Pessina A, Mazzoleni G. Paclitaxel-releasing mesenchymal stromal cells inhibit the growth of multiple myeloma cells in a dynamic 3D culture system. Hematol Oncol. 2017;35(4):693-702. DOI: 10.1002/hon.2306
Yasui H, Ishida T, Maruyama R, Nojima M, Ikeda H, Suzuki H, Hayashi T, Shinomura Y, Imai K. Model of translational cancer research in multiple myeloma. Cancer Sci. 2012;103(11):1907-12. DOI: 10.1111/j.1349-7006.2012.02384.x
Brancato V, Oliveira JM, Correlo VM, Reis RL, Kundu SC. Could 3D models of cancer enhance drug screening? Biomaterials. 2020 Feb;232:119744. doi: 10.1016/j.biomaterials.2019.119744. Epub 2019 Dec 26. PMID: 31918229
Villa A, Belloni D, Vergani B, Cenci S, Cavalli G, Biavasco R, Rodolfo M, Cangi MG, Doglioni C, Dagna L, Ferrero E, Ferrarini M. 3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target. Ann Rheum Dis. 2019;78(6):862-864. DOI: 10.1136/annrheumdis-2018-214432
Calimeri T, Battista E, Conforti F, Neri P, Di Martino MT, Rossi M, Foresta U, Piro E, Ferrara F, Amorosi A, Bahlis N, Anderson KC, Munshi N, Tagliaferri P, Causa F, Tassone P. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia. 2011:707-11. DOI 10.1038/leu.2010.300